The company plans to begin negotiations with private insurers to cover the NeuroNode as an in-network device. Credit: Chadchai Krisadapong / Shutterstock.

Control Bionics has received approval from the Centers for Medicare & Medicaid Services (CMS) for a new Healthcare Common Procedure Coding System (HCPCS) code for the NeuroNode sensor.

With the approval, the NeuroNode now qualifies for a $4,300 reimbursement, enhancing its accessibility in the US market.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The HCPCS Level II code, E2513, categorises NeuroNode as an “Accessory for speech generating device, electromyographic sensor”, acknowledging its unique EMG and 3D spatial movement capabilities.

The NeuroNode wireless, wearable sensor technology offers a breakthrough for users with conditions such as ALS and cerebral palsy, providing a non-invasive method for computer access and communication.

Its ability to interpret EMG signals and movements allows users to accurately control speech-generating devices, offering a transformative communication solution.

See Also:

The approval also presents an opportunity to establish a wholesale distribution model in the US, targeting the significant market of individuals diagnosed with ALS or cerebral palsy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The HCPCS E2513 code will be effective from 1 October 2024, enabling Control Bionics and its US partners to apply for the reimbursement.

Control Bionics will also begin negotiations with private insurers to cover the NeuroNode as an in-network device.

Control Bionics CEO Jeremy Steele said: “The introduction of the new HCPCS code for NeuroNode marks a significant milestone, not just for Control Bionics but for the countless individuals who rely on our technology to communicate and regain control of their lives.

“This recognition will greatly enhance accessibility, making it easier for patients to obtain the necessary support and devices through their insurance provider.”

“This code will expand our market reach, enabling us to bring our life-changing technology to a larger audience, and driving our mission to enhance communication and independence for those with severe disabilities.”